LABCORP HOLDINGS INC.

LH 10-K · FY 2025
API behind this page

LH FY 2025 request

Playground key active
Request URL /api/financials?ticker=LH&year=2025&quarter=4&full_year_mode=true
waiting 0 ms 
Pick an endpoint and run the request.
curl

Income Statement

JSON CSV Excel
Income Statement
Metric FY 2025 FY 2024 YoY
Revenue 13,951.7 13,008.9 +7.2%
Show Business Segments breakouts
Biopharma Laboratory Services · Operating Segments 3,098.2 2,922.6 +6.0%
Diagnostics [Member] · Operating Segments 10,876.5 10,144.3 +7.2%
Show Consolidation Items breakouts
Intersegment Elimination 23 58 -60.3%
Show Geographic Distribution breakouts
Geographic Distribution Domestic 11,650.1 10,858.3 +7.3%
Cost of Revenue 9,939.2 9,384.5 +5.9%
Gross Profit 4,012.5 3,624.4 +10.7%
Selling, General & Administrative 2,216.3 2,230 -0.6%
Amortization Of Intangible Assets 280 256.4 +9.2%
Asset Impairment Charges 4.3 5.3 -18.9%
Show Fair Value By Asset Class breakouts
Finite Lived Intangible Assets · Early Development 16 — —
Other Assets · Early Development 8.2 — —
Property Plant And Equipment · Early Development 61.4 — —
Net Restructuring And Other Charges 127.2 46 +176.5%
Show Reporting Unit breakouts
Early Development 105.5 — —
Operating Income 1,384.7 1,086.7 +27.4%
Show Business Segments breakouts
Biopharma Laboratory Services · Operating Segments 498.5 458.9 +8.6%
Corporate -482.2 -670.8 +28.1%
Diagnostics [Member] · Operating Segments 1,779.9 1,606.3 +10.8%
Show Consolidation Items breakouts
Operating Segments 2,278.4 2,065.2 +10.3%
Interest Expense -224.1 -208.3 -7.6%
Investment Income Net 15.2 22.3 -31.8%
Income Loss From Equity Method Investments -13.3 -1.4 -850.0%
Other Non-Operating Income (Expense) -55 60.2 -191.4%
Income Lossfrom Continuing Operations Before Income Taxesand Noncontrolling Interest 1,107.5 959.5 +15.4%
Income Tax Expense (Benefit) 229.8 212.4 +8.2%
Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest 877.7 747.1 +17.5%
Net Income 877.7 747.1 +17.5%
Net Income Loss Attributable To Noncontrolling Interest -1.2 -1.1 -9.1%
Net Income 876.5 746 +17.5%
Show Equity Components breakouts
Retained Earnings 876.5 746 +17.5%
Income Loss From Continuing Operations Per Basic Share 10.54 8.89 +18.6%
EPS (Basic) 10.54 8.89 +18.6%
Income Loss From Continuing Operations Per Diluted Share 10.46 8.84 +18.3%
EPS (Diluted) 10.46 8.84 +18.3%
Comprehensive Income 1,110.5 543.7 +104.2%
Wtd Avg Shares (Basic) 83.2 83.9 -0.8%
Wtd Avg Shares (Diluted) 83.8 84.4 -0.7%
Labor And Related Expense (FY) — — —
Show Business Segments breakouts
Biopharma Laboratory Services 1,221.6 1,165.3 +4.8%
Diagnostics [Member] 4,687.6 4,438.7 +5.6%

Balance Sheet

Balance Sheet
Metric FY 2025 FY 2024 YoY
Current Assets
Cash & Cash Equivalents 532.3 1,518.7 -65.0%
Accounts Receivable 2,103.8 1,944.1 +8.2%
Unbilled Contracts Receivable 156.9 152.9 +2.6%
Inventory 534.7 493.2 +8.4%
Prepaid Expenses & Other Current Assets 692.8 697.6 -0.7%
Total Current Assets 4,020.5 4,806.5 -16.4%
Non-Current Assets
Property, Plant & Equipment 3,081.5 3,045.4 +1.2%
Show Geography breakouts
Europe 370.4 355.5 +4.2%
North America 2,587.1 2,576.1 +0.4%
Other countries [Member] 124 113.8 +9.0%
Goodwill 6,789.5 6,369.7 +6.6%
Show Business Segments breakouts
Biopharma Laboratory Services 1,354.7 1,267.2 +6.9%
Diagnostics [Member] 5,434.8 5,102.5 +6.5%
Other Non-Current Assets 751.3 652.2 +15.2%
Total Assets 18,392.7 18,379 +0.1%
Operating Lease Right-of-Use Assets 803.9 784.5 +2.5%
Intangible Assets 3,036.8 2,931.4 +3.6%
Show Finite Lived Intangible Assets By Major Class breakouts
Customer Relationships 2,709 2,574 +5.2%
Noncompete Agreements 105.5 96.3 +9.6%
Other Intangible Assets 11.1 18.4 -39.7%
Patents, Licenses And Technology [Member] 211.2 242.7 -13.0%
Other Assets
Intangible Assets Net Excluding Goodwill 3,596 3,488.9 +3.1%
Investments In Affiliates Subsidiaries Associates And Joint Ventures 153.9 16.3 +844.2%
Current Liabilities
Accounts Payable 840.8 875.8 -4.0%
Accrued Liabilities 847.8 871.2 -2.7%
Deferred Revenue 439.1 392.2 +12.0%
Operating Lease Liability Current 191.1 184.6 +3.5%
Finance Lease Liability Current 4.6 6.1 -24.6%
Current Portion of Long-Term Debt 500.1 1,000.3 -50.0%
Total Current Liabilities 2,823.5 3,330.2 -15.2%
Non-Current Liabilities
Long-Term Debt 5,084.6 5,331.2 -4.6%
Operating Lease Liabilities 682.6 676.3 +0.9%
Finance Lease Liability Noncurrent 63 74.3 -15.2%
Deferred Income Taxes And Other Tax Liabilities Noncurrent 454.5 383.1 +18.6%
Other Non-Current Liabilities 647.8 517.4 +25.2%
Total Liabilities 9,756 10,312.5 -5.4%
Other Liabilities
Noncontrolling Interest Mezzanine Equity 16.9 14.3 +18.2%
Stockholders' Equity
Common Stock 7.5 7.6 -1.3%
Retained Earnings 8,639.9 8,303.4 +4.1%
Accumulated Other Comprehensive Income -27.6 -261.6 +89.4%
Total Stockholders' Equity 8,619.8 8,052.2 +7.0%
Show Equity Components breakouts
Accumulated Other Comprehensive Income -27.6 -261.6 +89.4%
Common Stock 7.5 7.6 -1.3%
Retained Earnings 8,639.9 8,303.4 +4.1%
Total Liabilities & Equity 18,392.7 18,379 +0.1%

Cash Flow Statement

Cash Flow Statement
Metric FY 2025 FY 2024 YoY
Operating Activities
Depreciation & Amortization 681.1 643.5 +5.8%
Show Property Plant And Equipment By Type breakouts
Property Plant And Equipment 401.1 387.1 +3.6%
Stock-Based Compensation 125.8 116.7 +7.8%
Operating Lease Right Of Use Asset Amortization Expense 208.1 185.3 +12.3%
Non Cash Portion Of Restructuring And Other Charges 101.3 — —
Increase Decrease In Deferred Income Taxes 97.6 -20.1 +585.6%
Other Operating Activities Cash Flow Statement 70.7 62.1 +13.8%
Change in Accounts Receivable -125.5 -52.3 -140.0%
Increase Decrease In Contract With Customer Asset 3.3 30.4 -89.1%
Change in Inventory -30.2 -12.6 -139.7%
Change in Prepaid & Other Assets -25.2 -54.5 +53.8%
Change in Accounts Payable -52.8 72.1 -173.2%
Increase Decrease In Deferred Revenue 34.6 -24.6 +240.7%
Increase Decrease In Accrued Liabilities And Other Operating Liabilities -330.3 -112.6 -193.3%
Net Cash Provided By Used In Operating Activities Continuing Operations 1,640.5 1,585.8 +3.4%
Net Cash from Operations 1,640.5 1,585.8 +3.4%
Deferred Income Taxes 97.6 -20.1 +585.6%
Investing Activities
Capital Expenditures -434.5 -489.9 +11.3%
Payments To Acquire Investments -192.4 -55 -249.8%
Proceeds From Sale Of Property Plant And Equipment 8 2 +300.0%
Proceeds From Sale Of Other Investments 6.9 — —
Payments To Acquire Businesses Net Of Cash Acquired -582 -839 +30.6%
Show Business Acquisition breakouts
Empire City Laboratories, Inc -250 — —
Parkview Health Systems, Inc. -165 — —
Net Cash Provided By Used In Investing Activities Continuing Operations -1,194 -1,366.8 +12.6%
Net Cash from Investing -1,194 -1,366.8 +12.6%
Financing Activities
Repayments Of Senior Debt -1,000 -1,000 0.0%
Proceeds From Accounts Receivable Securitization 225 300 -25.0%
Proceeds From Long Term Lines Of Credit 64.8 2,463.7 -97.4%
Repayments Of Lines Of Credit -64.8 -2,463.7 +97.4%
Tax Withholding for Share Compensation -31.9 -46.4 +31.2%
Net Proceeds From Issuance Of Stock To Employees 54.3 56.2 -3.4%
Payments Of Dividends -240.7 -243.1 +1.0%
Share Repurchases -450 -250.1 -79.9%
Proceeds From Payments For Other Financing Activities -13.7 -36.7 +62.7%
Net Cash Provided By Used In Financing Activities Continuing Operations -1,457 779.9 -286.8%
Net Cash from Financing -1,457 779.9 -286.8%
Supplemental
Income Taxes Paid 171.1 215.4 -20.6%
Other Cash Flow
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 24.1 -17 +241.8%
Net Change in Cash -986.4 981.9 -200.5%

Values in millions USD. Source: SEC EDGAR 10-K filing.

This table is rendered from the same JSON returned by /api/financials.

Get API Key